Loading
Loading
Research Overview
Single-molecule dual GLP-1R and amylin receptor co-agonist; integrates GLP-1-mediated appetite suppression and insulin sensitisation with amylin-mediated brainstem and hypothalamic satiety signalling in a single molecular entity.
Overview
Amycretin combines GLP-1 receptor agonism and amylin receptor agonism (AMY1-3) within a single molecular scaffold, eliminating the need for separate semaglutide and cagrilintide injections. The compound is under investigation in both subcutaneous (once-weekly) and oral (once-daily) formulations, with Phase 1/2 data providing early evidence for efficacy and tolerability.
The dual mechanism engages two complementary appetite-suppression pathways: GLP-1 receptor-mediated reduction of food intake and delayed gastric emptying, combined with amylin receptor-mediated satiety signalling in the brainstem and hypothalamus. Early trial data from the CagriSema programme (separate cagrilintide + semaglutide injection) has demonstrated approximately 25% weight loss with dual activation — amycretin aims to deliver comparable efficacy in a single agent.
Amycretin's early Phase 1/2 weight-loss data has been notable, with dose-escalation studies reporting weight reductions that appear to exceed semaglutide monotherapy benchmarks — consistent with the additive effect hypothesis from the CagriSema data. GI tolerability was reportedly milder than semaglutide alone, potentially enabling higher combined doses.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, amycretin has no TGA approval for therapeutic use. It is sold by Capital Precision Labs strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Single-molecule dual GLP-1R and amylin receptor co-agonist; integrates GLP-1-mediated appetite suppression and insulin sensitisation with amylin-mediated brainstem and hypothalamic satiety signalling in a single molecular entity.
Support
For research use only. Capital Precision Labs products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.